Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 5/20 | 0.72 |
| ▸ | CCR5 | P51681 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767709 | 0.91 | MLNR (0.69) | MLNRCCR5ALDH1A1CCR1CACNA1G | |
| SCHEMBL2766379 | 0.89 | MLNR (0.58) | MLNRCCR5ALDH1A1CCR1SIGMAR1 | |
| SCHEMBL13404693 | 0.88 | MLNR (0.66) | MLNRCCR5ALDH1A1ACHECHRM4 | |
| SCHEMBL2766816 | 0.88 | MLNR (0.57) | MLNRCCR5ALDH1A1KMT2A | |
| SCHEMBL3556504 | 0.87 | MLNR (0.75) | MLNRCCR5CHRM4 | |
| SCHEMBL2767269 | 0.84 | MLNR (1.00) | MLNR | |
| SCHEMBL2766459 | 0.84 | MLNR (0.60) | MLNRCCR5CHRM4CCR1 | |
| SCHEMBL3558154 | 0.83 | MLNR (0.72) | MLNRCCR5ALDH1A1CHRM4 | |
| SCHEMBL15152692 | 0.81 | MLNR (0.51) | MLNRCCR5ALDH1A1CCR1DRD4 | |
| SCHEMBL15152914 | 0.81 | MLNR (0.56) | MLNRCCR5CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |